{"id":38426,"date":"2026-04-15T09:23:45","date_gmt":"2026-04-15T07:23:45","guid":{"rendered":"https:\/\/ggba.swiss\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/"},"modified":"2026-04-15T09:26:14","modified_gmt":"2026-04-15T07:26:14","slug":"ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/","title":{"rendered":"AC Immune obtient CHF 10 millions de Lilly pour faire progresser sa th\u00e9rapie contre Alzheimer"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.acimmune.com\">AC Immune SA<\/a>, la soci\u00e9t\u00e9 biopharmaceutique lausannoise en phase clinique dont le si\u00e8ge est \u00e9tabli \u00e0 l&rsquo;<a href=\"https:\/\/www.epfl-innovationpark.ch\">EPFL Innovation Park<\/a>, a annonc\u00e9 un amendement \u00e0 son accord de licence et de collaboration de 2018 avec <a href=\"https:\/\/www.lilly.com\">Eli Lilly and Company<\/a> pour la recherche et le d\u00e9veloppement de petites mol\u00e9cules inhibitrices de l&rsquo;agr\u00e9gation de Tau. L&rsquo;accord amend\u00e9 \u00e9tend la collaboration pour couvrir de nouveaux candidats Tau Morphomer de t\u00eate et des compos\u00e9s de secours potentiels, avec le lancement des \u00e9tudes permettant le d\u00e9p\u00f4t d&rsquo;un IND (Investigational New Drug) pr\u00e9vu au premier semestre 2026.<\/p>\n\n\n\n<p>La plateforme Morphomer d&rsquo;AC Immune d\u00e9veloppe des petites mol\u00e9cules s\u00e9lectionn\u00e9es pour leur capacit\u00e9 \u00e0 p\u00e9n\u00e9trer le cerveau lorsqu&rsquo;elles sont administr\u00e9es par voie orale et \u00e0 se lier sp\u00e9cifiquement \u00e0 la conformation pathologique de la prot\u00e9ine Tau, un facteur cl\u00e9 de la neurod\u00e9g\u00e9n\u00e9rescence dans la maladie d&rsquo;Alzheimer et les pathologies associ\u00e9es. Les solides donn\u00e9es pr\u00e9cliniques g\u00e9n\u00e9r\u00e9es par AC Immune sugg\u00e8rent que les Tau Morphomers peuvent inhiber l&rsquo;agr\u00e9gation et l&rsquo;ensemencement \u00e0 travers de multiples stades pathologiques et de la maladie, des donn\u00e9es scientifiques croissantes indiquant que le ciblage de la Tau intracellulaire pourrait ralentir, voire stopper enti\u00e8rement la pathologie.<\/p>\n\n\n\n<p>Dans le cadre de l&rsquo;amendement, AC Immune recevra un paiement initial de CHF 10 millions et un paiement de jalon lors du dosage en Phase 1, en plus des jalons pr\u00e9c\u00e9demment annonc\u00e9s. La soci\u00e9t\u00e9 reste \u00e9ligible \u00e0 des jalons suppl\u00e9mentaires de d\u00e9veloppement, r\u00e9glementaires et commerciaux d\u00e9passant CHF 1,7 milliard, ainsi qu&rsquo;\u00e0 des redevances \u00e9chelonn\u00e9es \u00e0 deux chiffres bas.<\/p>\n\n\n\n<p>La collaboration avec Lilly est la derni\u00e8re d&rsquo;une s\u00e9rie de partenariats \u00e0 haute valeur s\u00e9curis\u00e9s par AC Immune, dont le bilan inclut un accord de <a href=\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\">USD 100 millions de paiement initial avec Takeda<\/a> pour son immunoth\u00e9rapie ACI-24.060 ciblant l&rsquo;amylo\u00efde b\u00eata, et la <a href=\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\">d\u00e9signation Fast Track de la FDA pour JNJ-2056<\/a>, son immunoth\u00e9rapie active anti-Tau d\u00e9velopp\u00e9e avec Janssen. Le pipeline de la soci\u00e9t\u00e9 repr\u00e9sente d\u00e9sormais plus de USD 4,5 milliards en paiements de jalons potentiels \u00e0 travers son portefeuille de programmes th\u00e9rapeutiques et diagnostiques.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune a amend\u00e9 son accord de licence et de collaboration avec Eli Lilly pour faire avancer de nouveaux candidats petites mol\u00e9cules Tau Morphomer contre la maladie d&rsquo;Alzheimer et d&rsquo;autres maladies neurod\u00e9g\u00e9n\u00e9ratives, avec le lancement des \u00e9tudes permettant le d\u00e9p\u00f4t d&rsquo;un IND pr\u00e9vu au premier semestre 2026.<\/p>\n","protected":false},"author":6,"featured_media":38423,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1181,1163,1171,1168],"class_list":["post-38426","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-medical-devices-fr","tag-medtech-fr-2","tag-pharma-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune obtient CHF 10 millions de Lilly | GGBa<\/title>\n<meta name=\"description\" content=\"AC Immune a amend\u00e9 son accord avec Eli Lilly pour faire avancer de nouveaux candidats Tau Morphomer contre la maladie d&#039;Alzheimer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune obtient CHF 10 millions de Lilly | GGBa\" \/>\n<meta property=\"og:description\" content=\"AC Immune a amend\u00e9 son accord avec Eli Lilly pour faire avancer de nouveaux candidats Tau Morphomer contre la maladie d&#039;Alzheimer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T07:23:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T07:26:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AC Immune obtient CHF 10 millions de Lilly pour faire progresser sa th\u00e9rapie contre Alzheimer\",\"datePublished\":\"2026-04-15T07:23:45+00:00\",\"dateModified\":\"2026-04-15T07:26:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/\"},\"wordCount\":394,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Medical Devices\",\"Medtech\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/\",\"name\":\"AC Immune obtient CHF 10 millions de Lilly | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"datePublished\":\"2026-04-15T07:23:45+00:00\",\"dateModified\":\"2026-04-15T07:26:14+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"AC Immune a amend\u00e9 son accord avec Eli Lilly pour faire avancer de nouveaux candidats Tau Morphomer contre la maladie d'Alzheimer.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"La plateforme Morphomer d'AC Immune d\u00e9veloppe des petites mol\u00e9cules con\u00e7ues pour p\u00e9n\u00e9trer le cerveau par voie orale et se lier sp\u00e9cifiquement aux formes pathologiques de la prot\u00e9ine Tau, ciblant un facteur cl\u00e9 de la neurod\u00e9g\u00e9n\u00e9rescence dans la maladie d'Alzheimer et les pathologies associ\u00e9es. | \u00a9 AC Immune\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune obtient CHF 10 millions de Lilly pour faire progresser sa th\u00e9rapie contre Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune obtient CHF 10 millions de Lilly | GGBa","description":"AC Immune a amend\u00e9 son accord avec Eli Lilly pour faire avancer de nouveaux candidats Tau Morphomer contre la maladie d'Alzheimer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/","og_locale":"fr_FR","og_type":"article","og_title":"AC Immune obtient CHF 10 millions de Lilly | GGBa","og_description":"AC Immune a amend\u00e9 son accord avec Eli Lilly pour faire avancer de nouveaux candidats Tau Morphomer contre la maladie d'Alzheimer.","og_url":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-04-15T07:23:45+00:00","article_modified_time":"2026-04-15T07:26:14+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AC Immune obtient CHF 10 millions de Lilly pour faire progresser sa th\u00e9rapie contre Alzheimer","datePublished":"2026-04-15T07:23:45+00:00","dateModified":"2026-04-15T07:26:14+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/"},"wordCount":394,"image":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","keywords":["Biotech","Financing","Medical Devices","Medtech","Pharma","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/","url":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/","name":"AC Immune obtient CHF 10 millions de Lilly | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","datePublished":"2026-04-15T07:23:45+00:00","dateModified":"2026-04-15T07:26:14+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"AC Immune a amend\u00e9 son accord avec Eli Lilly pour faire avancer de nouveaux candidats Tau Morphomer contre la maladie d'Alzheimer.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","width":1180,"height":811,"caption":"La plateforme Morphomer d'AC Immune d\u00e9veloppe des petites mol\u00e9cules con\u00e7ues pour p\u00e9n\u00e9trer le cerveau par voie orale et se lier sp\u00e9cifiquement aux formes pathologiques de la prot\u00e9ine Tau, ciblant un facteur cl\u00e9 de la neurod\u00e9g\u00e9n\u00e9rescence dans la maladie d'Alzheimer et les pathologies associ\u00e9es. | \u00a9 AC Immune"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-obtient-chf-10-millions-de-lilly-pour-faire-progresser-sa-therapie-contre-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"AC Immune obtient CHF 10 millions de Lilly pour faire progresser sa th\u00e9rapie contre Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/38426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=38426"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/38426\/revisions"}],"predecessor-version":[{"id":38428,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/38426\/revisions\/38428"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/38423"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=38426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=38426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=38426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}